MCID: LWG006
MIFTS: 41

Low Grade Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Low Grade Glioma

MalaCards integrated aliases for Low Grade Glioma:

Name: Low Grade Glioma 12
Benign Glioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080829
NCIt 50 C132067

Summaries for Low Grade Glioma

Disease Ontology : 12 A cell type benign neoplasm that has material basis in glial cells (astrocytes, oligodendrocytes or ependymocytes).

MalaCards based summary : Low Grade Glioma, also known as benign glioma, is related to pleomorphic xanthoastrocytoma and glioma susceptibility 1. An important gene associated with Low Grade Glioma is KAZALD1 (Kazal Type Serine Peptidase Inhibitor Domain 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Endometrial cancer. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and endothelial, and related phenotypes are behavior/neurological and mortality/aging

Related Diseases for Low Grade Glioma

Diseases related to Low Grade Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 pleomorphic xanthoastrocytoma 32.2 MGMT IDH2 IDH1
2 glioma susceptibility 1 31.5 IDH2 IDH1 ERBB2
3 oligoastrocytoma 31.5 MGMT IDH2
4 pilocytic astrocytoma 31.4 PROM1 MTOR MGMT IDH1
5 diffuse astrocytoma 31.3 MGMT IDH2 IDH1
6 oligodendroglioma 31.2 TP73 MGMT IDH2 IDH1
7 mixed glioma 31.1 MGMT IDH2 IDH1
8 brain glioma 30.7 MGMT IDH2 IDH1
9 gemistocytic astrocytoma 30.6 IDH2 IDH1
10 anaplastic oligodendroglioma 30.6 MGMT IDH2
11 malignant astrocytoma 30.6 PROM1 MIR125B1 MGMT IDH2 IDH1 ERBB2
12 brain cancer 30.5 TP73 MGMT IDH2 IDH1
13 mixed oligodendroglioma-astrocytoma 30.3 MGMT IDH2 IDH1
14 anaplastic astrocytoma 30.2 TP73 MGMT IDH2 IDH1
15 paronychia 30.0 MTOR ERBB2
16 gliofibroma 30.0 MGMT IDH1
17 glioblastoma 30.0 MTOR MIR125B2 MIR125B1 MGMT IDH2 IDH1
18 focal epilepsy 29.7 MTOR MAPT GABRD
19 medulloblastoma 28.7 TP73 PROM1 MTOR MGMT IDH1 ERBB2
20 neuroblastoma 28.3 TP73 PROM1 MTOR MAPT HSPA4 HSP90AA1
21 glioma 11.4
22 glial tumor 11.4
23 pituicytoma 11.2
24 neurofibromatosis 10.8
25 high grade glioma 10.7
26 allergic disease 10.4
27 low-grade astrocytoma 10.4
28 neutropenia 10.4
29 ganglioglioma 10.4
30 enchondroma 10.4 IDH2 IDH1
31 meningioma, familial 10.4
32 hydrocephalus 10.4
33 spinal meningioma 10.4
34 secretory meningioma 10.4
35 lymphoplasmacyte-rich meningioma 10.4
36 seizure disorder 10.4
37 cytogenetically normal acute myeloid leukemia 10.3 IDH2 IDH1
38 exanthem 10.3
39 optic pathway glioma 10.3
40 intracranial chondrosarcoma 10.3 IDH2 IDH1
41 frontal lobe neoplasm 10.3 MGMT IDH1
42 periosteal chondrosarcoma 10.3 IDH2 IDH1
43 adult oligodendroglioma 10.3 IDH2 IDH1
44 spinal cord astrocytoma 10.3 MGMT IDH1
45 juxtacortical chondroma 10.3 IDH2 IDH1
46 spinal cord oligodendroglioma 10.3 MGMT IDH1
47 adult brain stem glioma 10.3 MGMT IDH2 IDH1
48 childhood oligodendroglioma 10.3 MGMT IDH2 IDH1
49 adult astrocytic tumour 10.2 IDH2 IDH1
50 neurofibromatosis, type i 10.2

Graphical network of the top 20 diseases related to Low Grade Glioma:



Diseases related to Low Grade Glioma

Symptoms & Phenotypes for Low Grade Glioma

MGI Mouse Phenotypes related to Low Grade Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ERBB2 ETV5 GABRD HSP90AA1 HSPA4 HSPD1
2 mortality/aging MP:0010768 10.1 ERBB2 ETV5 GABRD HSP90AA1 HSPA4 HSPD1
3 cellular MP:0005384 10.06 ERBB2 ETV5 HSP90AA1 HSPA4 HSPD1 MAPT
4 nervous system MP:0003631 9.77 ERBB2 ETV5 GABRD HSP90AA1 HSPA4 HSPD1
5 neoplasm MP:0002006 9.63 ERBB2 IDH2 MAPT MGMT PROM1 TP73
6 respiratory system MP:0005388 9.23 ERBB2 ETV5 HSPD1 IDH1 MGMT MTOR

Drugs & Therapeutics for Low Grade Glioma

Drugs for Low Grade Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3 Protein Kinase Inhibitors Phase 4
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
7
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
8
Vinblastine Approved Phase 3 865-21-4 13342 241903
9
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
10 Antimitotic Agents Phase 3
11 Tubulin Modulators Phase 3
12 Alkylating Agents Phase 3
13
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
14
Hydroxyurea Approved Phase 2 127-07-1 3657
15
Carmustine Approved, Investigational Phase 2 154-93-8 2578
16
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
17
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
18
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
19
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
20
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
21
Acetaminophen Approved Phase 2 103-90-2 1983
22
Dimethyl sulfoxide Approved, Vet_approved Phase 1, Phase 2 67-68-5 679
23
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
24
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
26
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
27
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
28
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
29
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
30
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
31
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
33
Threonine Approved, Nutraceutical Phase 2 72-19-5 6288
34
Camptothecin Experimental Phase 2 7689-03-4
35
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
36 Imatinib Mesylate Phase 2 220127-57-1 123596
37 Immunoglobulins Phase 2
38 Antibodies Phase 2
39 Antibodies, Monoclonal Phase 2
40 Immunoglobulin G Phase 2
41 Radiopharmaceuticals Phase 2
42 Deoxyglucose Phase 2
43 Fluorides Phase 2
44 Antiviral Agents Phase 2
45 Antimetabolites Phase 2
46 Fluorodeoxyglucose F18 Phase 2
47 Immunoglobulins, Intravenous Phase 2
48 Endothelial Growth Factors Phase 2
49 Angiogenesis Inhibitors Phase 1, Phase 2
50 Antineoplastic Agents, Immunological Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
3 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
4 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
6 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
7 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Recruiting NCT03763422 Phase 3 Temozolomide
8 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
9 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Recruiting NCT02455245 Phase 3 Carboplatin;Vincristine
10 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
11 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
12 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
13 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
14 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
15 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
16 A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Unknown status NCT01188096 Phase 2 Poly ICLC
17 Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs) Unknown status NCT00575796 Phase 2 Vinblastine Sulphate
18 A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas Unknown status NCT02209428 Phase 2 Temozolomide
19 Phase 2 Study of Weekly Vinorelbine in Children With Progressive or Recurrent Low-Grade Gliomas Completed NCT01497860 Phase 2 Vinorelbine
20 Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma Completed NCT02197637 Phase 2 ORAL VINORELBINE
21 A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma Completed NCT00313729 Phase 2 temozolomide
22 Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
23 A Phase 2 Study of Vinblastine Sulphate Injection in Children With Recurrent or Refractory Low Grade Glioma Completed NCT00213278 Phase 2 vinblastine sulphate injection
24 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
25 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
26 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
27 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 Everolimus
28 A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma Completed NCT01635283 Phase 2
29 A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas Completed NCT00238264 Phase 2
30 A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Completed NCT01158651 Phase 2 RAD001 (Everolimus)
31 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
32 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
33 Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal Completed NCT00003466 Phase 2 temozolomide
34 PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS Completed NCT00002806 Phase 2 lomustine;procarbazine hydrochloride;vincristine sulfate
35 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
36 A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas Completed NCT00782626 Phase 2 everolimus
37 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
38 A Prospective, Singal-arm Clinical Study of Recombinant Human Endostatin (ENDOSTAR) Combined With Carboplatin and Vincristine in the Treatment of Low-grade Gliomas in Children Recruiting NCT04659421 Phase 2 combined therapy with rh-ES and CV
39 A Phase II Study of Vaccinations With HLA-A2 Restricted Glioma Antigen Peptides in Combination With Poly-ICLC for Children With Recurrent Unresectable Low-Grade Gliomas (LGG) Recruiting NCT02358187 Phase 2
40 A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway. Recruiting NCT03363217 Phase 1, Phase 2 Trametinib
41 Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults Recruiting NCT04201457 Phase 1, Phase 2 Dabrafenib;Trametinib;Hydroxychloroquine
42 A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG) Recruiting NCT02840409 Phase 2 Vinblastine;Bevacizumab
43 SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
44 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
45 PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma Active, not recruiting NCT02023905 Phase 2 Everolimus;Temozolomide
46 A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Active, not recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
47 Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma Active, not recruiting NCT01887522 Phase 2 Vinblastine + Nilotinib;Vinblastine
48 PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Active, not recruiting NCT01734512 Phase 2 Everolimus
49 Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors Active, not recruiting NCT02285439 Phase 1, Phase 2 MEK162
50 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Active, not recruiting NCT00187226 Phase 2

Search NIH Clinical Center for Low Grade Glioma

Genetic Tests for Low Grade Glioma

Anatomical Context for Low Grade Glioma

MalaCards organs/tissues related to Low Grade Glioma:

40
Brain, Cortex, Endothelial, Temporal Lobe, Spinal Cord, Pituitary, T Cells

Publications for Low Grade Glioma

Articles related to Low Grade Glioma:

(show top 50) (show all 2089)
# Title Authors PMID Year
1
Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas. 61
33332981 2021
2
Personality and behavioral changes after brain tumor resection: a lesion mapping study. 61
33576912 2021
3
The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial. 61
33543269 2021
4
Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes. 61
33567561 2021
5
Presenting symptoms and time to diagnosis for Pediatric Central Nervous System Tumors in Qatar: a report from Pediatric Neuro-Oncology Service in Qatar. 61
32710251 2021
6
Benefit of Static FET PET in Pretreated Pediatric Brain Tumor Patients with Equivocal Conventional MRI Results. 61
33598897 2021
7
Advances in the classification and treatment of pediatric brain tumors. 61
33278109 2021
8
Low-grade glioma: A rare second tumor in retinoblastoma survivors. 61
33063942 2021
9
Diffuse midline glioma presenting with central sleep apnea and pulmonary hypertension in a 4-year-old patient: a case report. 61
33006310 2021
10
Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA. 61
33454543 2021
11
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. 61
33140540 2021
12
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. 61
33557783 2021
13
m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma. 61
33594424 2021
14
[Low grade glioma with MYBL1 alteration: Case report of an uncommon pediatric neoplasm]. 61
32732147 2021
15
Intraoperative MRI and FLAIR Analysis: Implications for low-grade glioma surgery. 61
31563588 2021
16
Expression and prognostic characteristics of m5 C regulators in low-grade glioma. 61
33400376 2021
17
A novel DNA repair-related nomogram predicts survival in low-grade gliomas. 61
33063446 2021
18
Global microRNA profiling identified miR-10b-5p as a regulator of neurofibromatosis 1 (NF1)-glioma migration. 61
32603552 2021
19
Return to work in survivors of Primary Brain Tumours treated with Intensity Modulated Radiotherapy. 61
33440331 2021
20
The Merits of Awake Craniotomy for Glioblastoma in the Left Hemispheric Eloquent Area: One Institution Experience. 61
33158628 2021
21
Awake Craniotomy in Low-Resource Settings: Findings from a Retrospective Cohort in the Philippines. 61
33091650 2021
22
Spatial Agreement of Brainstem Dose Distributions Depending on Biological Model in Proton Therapy for Pediatric Brain Tumors. 61
33490724 2021
23
Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma. 61
33475317 2021
24
Patterns of axono-cortical evoked potentials: an electrophysiological signature unique to each white matter functional site? 61
33433683 2021
25
Intraoperative MRI-guided Resection in Pediatric Brain Tumor Surgery: A Meta-analysis of Extent of Resection and Safety Outcomes. 61
32968998 2021
26
Virtual Monochromatic Image Quality from Dual-Layer Dual-Energy Computed Tomography for Detecting Brain Tumors. 61
33569932 2021
27
Glioma-Derived TSP2 Promotes Excitatory Synapse Formation and Results in Hyperexcitability in the Peritumoral Cortex of Glioma. 61
33382873 2021
28
Evaluation of magnetic resonance image segmentation in brain low-grade gliomas using support vector machine and convolutional neural network. 61
33392030 2021
29
Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Healthcare Models. 61
33476782 2021
30
Executive functional deficits during electrical stimulation of the right frontal aslant tract. 61
33462780 2021
31
Adaptive Proton Therapy for Pediatric Patients: Improving the Quality of the Delivered Plan With On-Treatment MRI. 61
33129626 2021
32
Texture analysis of apparent diffusion coefficient (ADC) map for glioma grading: Analysis of whole tumoral and peri-tumoral tissue. 61
33419692 2021
33
Current Salvage Treatment Strategies for Younger Children (<10 y of Age) With Progressive Low-grade Glioma After Initial Chemotherapy in North America: A Web-based Survey. 61
33235141 2021
34
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma. 61
32681754 2021
35
Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis. 61
33545929 2021
36
Homotopic redistribution of functional connectivity in insula-centered diffuse low-grade glioma. 61
33508623 2021
37
How can scanned proton beam treatment planning for low-grade glioma cope with increased distal RBE and locally increased radiosensitivity for late MR-detected brain lesions? 61
33506555 2021
38
Predicting the Extent of Resection in Low-Grade Glioma by Using Intratumoral Tractography to Detect Eloquent Fascicles Within the Tumor. 61
33313812 2021
39
Contralesional functional network reorganization of the insular cortex in diffuse low-grade glioma patients. 61
33436741 2021
40
EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma. 61
33545987 2021
41
Cognitive reserve protects language functions in patients with brain tumours. 61
33524456 2021
42
A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma. 61
33550903 2021
43
Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours. 61
33398536 2021
44
IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions. 61
33492489 2021
45
Neuropsychological assessments before and after awake surgery for incidental low-grade gliomas. 61
33276332 2020
46
Bur Hole-Based Resections of Intrinsic Brain Tumors with Exoscopic Visualization. 61
33352611 2020
47
EZH2 is a potential prognostic predictor of glioma. 61
33277782 2020
48
Altered Motor Excitability in Patients With Diffuse Gliomas Involving Motor Eloquent Areas: The Impact of Tumor Grading. 61
32888309 2020
49
Screening and functional prediction of differentially expressed circular RNAs in human glioma of different grades. 61
33323543 2020
50
Genetic, cellular, and connectomic characterization of the brain regions commonly plagued by glioma. 61
33278823 2020

Variations for Low Grade Glioma

Expression for Low Grade Glioma

Search GEO for disease gene expression data for Low Grade Glioma.

Pathways for Low Grade Glioma

Pathways related to Low Grade Glioma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.09 TP73 MDK MAPT HSPA4 HSP90AA1 ERBB2
2
Show member pathways
12.65 NFKB1 MTOR HSP90AA1 ETV5 ERBB2
3
Show member pathways
12.22 NFKB1 MTOR GABRD ERBB2
4 12.15 NFKB1 MTOR MIR125B2 MIR125B1 ERBB2
5
Show member pathways
11.87 NFKB1 MTOR MIR125B2 MIR125B1
6
Show member pathways
11.85 NFKB1 HSP90AA1 ERBB2
7 11.79 TP73 NFKB1 ERBB2
8
Show member pathways
11.78 NFKB1 MTOR ETV5
9 11.75 NFKB1 MTOR ERBB2
10 11.56 HSPD1 HSPA4 HSP90AA1
11
Show member pathways
11.44 NFKB1 MTOR HSP90AA1
12 11.4 NFKB1 MTOR HSP90AA1
13 11.11 NFKB1 HSPA4 HSP90AA1
14 11.1 MTOR IDH2 IDH1 ERBB2
15 10.81 PROM1 MTOR ERBB2
16
Show member pathways
10.64 IDH2 IDH1
17 10.46 HSPA4 HSP90AA1

GO Terms for Low Grade Glioma

Cellular components related to Low Grade Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.56 PROM1 MIR125B2 MIR125B1 IDH2 IDH1 HSPD1
2 secretory granule lumen GO:0034774 9.33 NFKB1 IDH1 HSP90AA1
3 mitochondrion GO:0005739 9.28 TP73 NFKB1 MTOR MAPT IDH2 IDH1

Biological processes related to Low Grade Glioma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.76 MTOR MIR125B1 HSP90AA1 ERBB2
2 regulation of cellular response to heat GO:1900034 9.72 MTOR MAPT HSP90AA1
3 response to unfolded protein GO:0006986 9.7 HSPD1 HSPA4 HSP90AA1
4 positive regulation of keratinocyte differentiation GO:0045618 9.6 MIR125B2 MIR125B1
5 negative regulation of keratinocyte proliferation GO:0010839 9.59 MIR125B2 MIR125B1
6 2-oxoglutarate metabolic process GO:0006103 9.58 IDH2 IDH1
7 cellular response to vitamin D GO:0071305 9.58 MIR125B2 MIR125B1
8 cellular response to heat GO:0034605 9.58 MAPT HSPD1 HSP90AA1
9 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.57 MIR125B2 MIR125B1
10 NADP metabolic process GO:0006739 9.56 IDH2 IDH1
11 negative regulation of monocyte differentiation GO:0045656 9.54 MIR125B2 MIR125B1
12 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.51 MIR125B2 MIR125B1
13 negative regulation of STAT cascade GO:1904893 9.49 MIR125B2 MIR125B1
14 positive regulation of tau-protein kinase activity GO:1902949 9.48 MIR125B1 HSP90AA1
15 isocitrate metabolic process GO:0006102 9.43 IDH2 IDH1
16 positive regulation of oligodendrocyte differentiation GO:0048714 9.43 TP73 MTOR MDK
17 protein import into mitochondrial outer membrane GO:0045040 9.37 HSPA4 HSP90AA1
18 cellular response to interleukin-6 GO:0071354 9.33 NFKB1 MIR125B2 MIR125B1
19 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
20 chaperone-mediated protein complex assembly GO:0051131 9.13 HSPD1 HSPA4 HSP90AA1
21 positive regulation of glial cell proliferation GO:0060252 8.92 MTOR MIR125B2 MIR125B1 ETV5

Molecular functions related to Low Grade Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TP73 NFKB1 MTOR MAPT IDH1 HSP90AA1
2 apolipoprotein binding GO:0034185 9.32 MAPT HSPD1
3 actinin binding GO:0042805 9.16 PROM1 NFKB1
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
5 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Low Grade Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....